

# COVID-19 Vaccine

## Interim COVID-19 Immunization Schedule for 6 Months of Age and Older



The table below provides guidance for COVID-19 vaccination schedules based on age and medical condition. Scheduling considerations include:

- Administer the appropriate vaccine product based on the recipient's age and the product's age indications.
- COVID-19 vaccines may be administered on the same day as other vaccines.
- Doses administered at any time after the intervals outlined below are valid.

Detailed information can be found in CDC's Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States, see: [www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html)

**Table 1. Immunization Schedule for Children 6 Months through 17 Years of Age**

Type	Product*	Recipient Age	For Most People		Those Who ARE Moderately or Severely Immunocompromised	
			Doses	Interval Between Doses <sup>†‡</sup>	Doses	Interval Between Doses <sup>†‡</sup>
mRNA vaccine	Moderna (Blue vial cap with magenta-bordered label)	6 months through 5 years	Total doses: 2 doses		Total doses: 3 doses	
			Dose 1 to 2	At least 4–8 weeks <sup>†</sup>	Dose 1 to 2	At least 4 weeks
	Moderna (Blue vial cap with purple-bordered label)	6 through 11 years	Total doses: 2 doses		Total doses: 3 doses	
			Dose 1 to 2	At least 4–8 weeks <sup>†</sup>	Dose 1 to 2	At least 4 weeks
	Moderna (Red vial cap with blue-bordered label)	12 through 17 years	Total doses: 2 doses		Total doses: 3 doses	
			Dose 1 to 2	At least 4–8 weeks <sup>†</sup>	Dose 1 to 2	At least 4 weeks
	Pfizer-BioNTech (Maroon vial cap with maroon-bordered label)	6 months through 4 years	Total number: 3 doses		Total number: 3 doses	
			Dose 1 to 2	At least 3–8 weeks <sup>†</sup>	Dose 1 to 2	At least 3 weeks
			Doses 2 and 3	At least 8 weeks	Dose 2 to 3	At least 8 weeks
	Pfizer-BioNTech (Orange vial cap with orange-bordered label)	5 through 11 years	Total number: 3 doses		Total number: 4 doses	
			Dose 1 to 2	At least 3–8 weeks <sup>†</sup>	Dose 1 to 2	At least 3 weeks
			Dose 2 to 3	At least 5 months	Dose 2 to 3	At least 4 weeks
Pfizer-BioNTech (Purple vial cap with a purple-bordered label or gray vial cap with gray-bordered label)	12 years through 17 years	Total number: 3 doses		Total number: 5 doses		
		Dose 1 to 2	At least 3–8 weeks <sup>†</sup>	Dose 1 to 2	At least 3 weeks	
		Dose 2 to 3	At least 5 months	Dose 2 to 3	At least 4 weeks	
				Dose 3 to 4	At least 3 months	
Dose 4 to 5	At least 4 months	Dose 4 to 5	At least 4 months			
		Novavax	12 years and older	Total number: 2 doses <sup>†</sup>		Total number: 2 doses
Dose 1 to 2	At least 3–8 weeks <sup>†</sup>			Dose 1 to 2	At least 3 weeks	

\* Complete the primary series with same product. If the vaccine product previously administered cannot be determined, is no longer available or contraindicated, any age-appropriate COVID-19 vaccine product may be administered at least 28 days after the first dose. An mRNA (Moderna, Pfizer-BioNTech) and Novavax COVID-19 vaccines are recommended for the primary series. The mRNA vaccines are recommended for booster doses. Novavax COVID-19 Vaccine is not authorized for booster doses. Janssen COVID-19 Vaccine should only be used in limited situations.

<sup>†</sup> Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

<sup>‡</sup> Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA or Novavax COVID-19 Vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months–64 years, especially for males ages 12–39 years.

# COVID-19 Vaccine

Interim COVID-19 Immunization Schedule  
for 6 Months of Age and Older



**Table 2. Immunization Schedule for Persons 18 Years of Age**

Type	Product*	Recipient Age	For Most People		Those Who ARE Moderately or Severely Immunocompromised	
			Doses	Interval Between Doses <sup>†‡</sup>	Doses	Interval Between Doses <sup>†‡</sup>
mRNA vaccine	Moderna (Red vial cap with a blue-bordered label)	18 years and older	Total number: 3 or 4 doses		Total number: 5 doses	
			Dose 1 to 2	At least 4–8 weeks <sup>†</sup>	Dose 1 to 2	At least 4 weeks
			Dose 2 to 3 <sup>§</sup>	At least 5 months	Dose 2 to 3	At least 4 weeks
			Dose 3 to 4 <sup>§</sup>	At least 4 months for persons ages 50 years and older	Dose 3 to 4 <sup>§</sup>	At least 3 months
	Dose 4 to 5 <sup>§</sup>	At least 4 months				
	Pfizer-BioNTech (Purple vial cap with a purple-bordered label or gray vial cap with gray-bordered label)	18 years and older	Total number: 3 or 4 doses		Total number: 5 doses	
			Dose 1 to 2	At least 3-8 weeks <sup>†</sup>	Dose 1 to 2	At least 3 weeks
			Dose 2 to 3	At least 5 months <sup>§</sup>	Dose 2 to 3	At least 4 weeks
Dose 3 to 4			At least 4 months for persons ages 50 years and older <sup>§</sup>	Dose 3 to 4 <sup>§</sup>	At least 3 months	
	Dose 4 to 5 <sup>§</sup>	At least 4 months				
Protein subunit vaccine	Novavax	12 years and older	Total number: 2 doses <sup>†</sup>		Total number: 2 doses	
			Dose 1 to 2	At least 3–8 weeks <sup>†</sup>	Dose 1 to 2	At least 3 weeks
Adenovirus vector vaccine	Janssen*	18 years and older	Janssen COVID-19 vaccine is authorized for use in certain limited situations due to safety considerations. <sup>¶</sup>			

\* Complete the primary series with same product. If the vaccine product previously administered cannot be determined, is no longer available or contraindicated, any age-appropriate COVID-19 vaccine product may be administered at least 28 days after the first dose. An mRNA (Moderna, Pfizer-BioNTech) and Novavax COVID-19 vaccines are recommended for the primary series. The mRNA vaccines are recommended for booster doses. Novavax COVID-19 Vaccine is not authorized for booster doses. Janssen COVID-19 Vaccine should only be used in limited situations.

† Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA or Novavax COVID-19 Vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 6 months–64 years, especially for males ages 12–39 years.

§ mRNA vaccine recommended. Novavax COVID-19 Vaccine is not authorized for booster dose.

¶ For guidance on retrospective record review, scheduling and administration see [www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a)

# COVID-19 Vaccine

## Interim COVID-19 Immunization Schedule for 6 Months of Age and Older




### Special Situations When Vaccinating Children

1. COVID-19 vaccine from the same manufacturer should be used for the primary series. If a different manufacturer is administered, follow the guidance below:

- If a dose of the age-appropriate product from BOTH Moderna and Pfizer-BioNTech COVID-19 is given, count both doses if the recommended interval between doses has been met.
  - Complete the series following the Pfizer-BioNTech 3-dose schedule using an age-appropriate vaccine from either manufacturer. See examples.
  - Repeating doses is not recommended.
- This guidance applies to:
  - All eligible children, including those who are moderately or severely immunocompromised.
  - Vaccines from both manufacturers, regardless which vaccine was given first.

### Examples:

**Vaccination history:** 1 dose of Pfizer-BioNTech and 1 dose of Moderna COVID-19 vaccines.



2. Children who have a birthday before completing the primary series

- Vaccine product and dosage (amount of vaccine given) is determined by the recipient's age.
- CDC recommends administering the age-appropriate product based on the child's age the day the vaccine will be administered – even if the series was started with a vaccine with younger age indications.
- If a dose(s) of the vaccine product indicated for the younger age group is administered, count the dose(s). Revaccination is not indicated. It is NOT considered a vaccine administration error.
- For detailed guidance see:
  - Pfizer-BioNTech COVID-19 Vaccine: For Children who Transition from a Younger to Older Age Group ([www.cdc.gov/vaccines/covid-19/downloads/Pfizer-Child-Age-Transition-508.pdf](http://www.cdc.gov/vaccines/covid-19/downloads/Pfizer-Child-Age-Transition-508.pdf))
  - Moderna COVID-19 Vaccine: For Children who Transition from a Younger to Older Age Group ([www.cdc.gov/vaccines/covid-19/downloads/Moderna-Child-Age-Transition-508.pdf](http://www.cdc.gov/vaccines/covid-19/downloads/Moderna-Child-Age-Transition-508.pdf))

# COVID-19 Vaccine

Interim COVID-19 Immunization Schedule  
for 6 Months of Age and Older



**Table 3. COVID-19 Vaccine Products Summary**

Product*	Age Indications†	Diluent	Dose/Injection Amount
<b>Type: mRNA vaccine</b>			
<b>Moderna</b> (Blue vial cap with magenta-bordered label)	6 months through 5 years	NONE	Any dose in the primary series. Booster doses are not recommended for this age group. 25 µg/ 0.25 mL
<b>Moderna</b> (Blue vial cap with purple-bordered label)	6 through 11 years	NONE	Any dose in the primary series. Booster doses are not authorized for children, ages 6 through 11 years, who received a Moderna primary series. 50 µg/0.5 mL
	18 years and older	NONE	Booster dose only. 50 µg/0.5 mL
<b>Moderna</b> (Red vial cap with blue-bordered label)	12 years and older	NONE	Any dose in the primary series. Booster doses are not authorized for adolescents, ages 12 through 17 years, who received a Moderna primary series. 100 µg/ 0.5 mL
	18 years and older	NONE	Any dose in the primary series. 100 µg/ 0.5 mL
			Booster dose 50 µg/ 0.25 mL
<b>Pfizer-BioNTech</b> (Maroon vial cap with maroon-bordered label)	6 months through 4 years	2.2 mL 0.9% sodium chloride (normal saline, preservative-free)	Any dose in the primary series. Booster doses are not recommended for this age group. 3 µg/0.2 mL
<b>Pfizer-BioNTech</b> (Orange vial cap with orange-bordered label)	5 through 11 years	1.3 mL 0.9% sodium chloride (normal saline, preservative-free)	Any dose in the primary series and booster doses. 10 µg/0.2 mL
<b>Pfizer-BioNTech</b> (Purple vial cap with a purple-bordered label)	12 years and older	1.8 mL 0.9% sodium chloride (normal saline, preservative-free)	Any dose in the primary series and booster doses. 30 µg/0.3 mL
<b>Pfizer-BioNTech</b> (Gray vial cap with a gray-bordered label)	12 years and older	NONE	Any dose in the primary series and booster doses. 30 µg/0.3 mL
Product	Age Indications	Diluent	Dose/Injection Amount
<b>Type: Protein sub unit vaccine</b>			
<b>Novavax</b> (Royal blue cap)	12 years and older	NONE	Any dose in the primary series. Persons who received a Novavax COVID-19 Vaccine primary series are not eligible for booster doses (any product). 5 µg rS and 50 µg of Matrix-M™ adjuvant/0.5 mL
Product	Age Indications	Diluent	Dose/Injection Amount
<b>Type: Viral vector vaccine</b>			
<b>Janssen</b> (Blue Cap)	18 years and older	NONE	Janssen COVID-19 vaccine is authorized for use in certain limited situations due to safety considerations.‡ 5×10 <sup>10</sup> viral particles/0.5 mL

\* Complete the primary series with same product. If the vaccine product previously administered cannot be determined, is no longer available or contraindicated, any age-appropriate COVID-19 vaccine product may be administered at least 28 days after the first dose. An mRNA (Moderna, Pfizer-BioNTech) and Novavax COVID-19 vaccines are recommended for the primary series. The mRNA vaccines are recommended for booster doses. Novavax COVID-19 Vaccine is not authorized for booster doses. Janssen COVID-19 Vaccine should only be used in limited situations.

† Administer the appropriate vaccine product based on the recipient's age and the vaccine product's age indications.

‡ For guidance on retrospective record review, scheduling and administration see [www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a)

## CDC Resources

CDC COVID-19 vaccine clinical training and materials at: [www.cdc.gov/vaccines/covid-19/info-by-product/index.html](https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html)

CDC Interim Clinical Considerations for the Use of COVID-19 Vaccines Currently Approved or Authorized in the United States at: [www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#primary-series](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#primary-series)

CDC Vaccine administration clinical materials at: [www.cdc.gov/vaccines/hcp/admin/resource-library.html](https://www.cdc.gov/vaccines/hcp/admin/resource-library.html)

CDC Vaccine Storage and Handling Toolkit at: [www.cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html](https://www.cdc.gov/vaccines/hcp/admin/storage/toolkit/index.html)